Overview

A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test any good and bad effect of the study drug, onapristone extended-release (ER) alone and in combination with anastrozole.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Context Therapeutics
Treatments:
Anastrozole
Onapristone
Progesterone